宫腔粘连分离术后预防粘连复发的方法及研究进展

doi:10.12280/gjfckx.20201136

摘要/Abstract

摘要：

宫腔粘连（intrauterine adhesions,IUA）是指由于多种因素导致子宫内膜基底层受损,临床症状主要表现为月经异常、不孕、复发性流产及早产、胎盘异常等产科相关并发症。宫腔镜手术是治疗IUA的标准术式,但是中、重度IUA患者术后的复发率较高,严重影响患者的生殖预后。目前临床上预防术后粘连复发的方法包括雌激素或其他药物促进内膜修复、宫腔内放置支架、透明质酸抑制创面炎症反应、宫腔内放置羊膜制品、宫腔镜二次探查、治疗慢性子宫内膜炎等。还有一些尚在研究阶段的新措施,如宫腔注射促子宫内膜生长因子、干细胞治疗等。在临床实际应用过程中,目前尚无统一的治疗方案,多采取多种措施综合治疗。

关键词: 组织黏连, 子宫, 宫腔粘连, 复发, 雌激素类, 球囊和椭圆囊, 羊膜

Abstract:

Intrauterine adhesions (IUA) refers to the damage of endometrial basal layer caused by many factors. Patients with IUA may present with menstrual abnormalities, infertility, recurrent miscarriages. Sequelae of pregnancy in the presence of adhesions include higher incidences of premature labor, and abnormal placentation. Hysteroscopic surgery is the standard operation for the treatment of IUA. However, the recurrence rate of adhesions in patients with moderate to severe IUA is high, which seriously affects the reproductive prognosis of patients. At present, the clinical methods to prevent postoperative adhesion recurrence include promoting endometrial growth and repair with estrogen or other drugs, stent placement in the uterine cavity, inhibiting the inflammatory reaction of the wound with hyaluronic acid, amniotic membrane products placement in the uterine cavity, second-look hysteroscopy, treatment of chronic endometritis, etc. There are still some new measures in the research stage, such as intrauterine injection of endometrial growth factor, stem cell therapy and so on. In the clinical practice, there is no unified treatment plan nowadays, and most patients are treated with a combination regimen.

Key words: Tissue adhesions, Uterus, Intrauterine adhesions, Recurrence, Estrogens, Saccule and utricle, Amnion

蒋文军, 黄晓武. 宫腔粘连分离术后预防粘连复发的方法及研究进展[J]. 国际妇产科学杂志, 2021, 48(4): 409-414.

JIANG Wen-jun, HUANG Xiao-wu. Methods and Research Advances in Prevention of the Recurrence of IUA after Hysteroscopic Adhesiolysis[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 409-414.

参考文献 40

[1]	Yu D, Wong YM, Cheong Y, et al. Asherman syndrome--one century later[J]. Fertil Steril, 2008, 89(4):759-779. doi: 10.1016/j.fertnstert.2008.02.096. doi: 10.1016/j.fertnstert.2008.02.096
[2]	中华医学会妇产科学分会. 宫腔粘连临床诊疗中国专家共识[J]. 中华妇产科杂志, 2015, 50(12):881-887. doi: 10.3760/cma.j.issn.0529-567x.2015.12.001. doi: 10.3760/cma.j.issn.0529-567x.2015.12.001
[3]	赵淑芬, 柳怡, 郑雪湘. 宫腔粘连患者子宫内膜组织中雌激素受体及孕激素受体的表达情况和临床意义分析[J]. 中国计划生育和妇产科, 2018, 10(7):33-36,41. doi: 10.3969/j.issn.1674-4020.2018.07.08. doi: 10.3969/j.issn.1674-4020.2018.07.08
[4]	AAGL Practice Report: Practice Guidelines on Intrauterine Adhesions Developed in Collaboration With the European Society of Gynaecological Endoscopy(ESGE)[J]. J Minim Invasive Gynecol, 2017, 24(5):695-705. doi: 10.1016/j.jmig.2016.11.008. doi: 10.1016/j.jmig.2016.11.008
[5]	Kou L, Jiang X, Xiao S, et al. Therapeutic options and drug delivery strategies for the prevention of intrauterine adhesions[J]. J Control Release, 2020, 318:25-37. doi: 10.1016/j.jconrel.2019.12.007. doi: 10.1016/j.jconrel.2019.12.007
[6]	贺红菊, 邢璐, 张欢, 等. 宫腔镜宫腔粘连分离术后雌激素用量及其效果的Meta分析[J]. 实用妇产科杂志, 2018, 34(10):763-768.
[7]	Liu AZ, Zhao HG, Gao Y, et al. Effectiveness of estrogen treatment before transcervical resection of adhesions on moderate and severe uterine adhesion patients[J]. Gynecol Endocrinol, 2016, 32(9):737-740. doi: 10.3109/09513590.2016.1160375. doi: 10.3109/09513590.2016.1160375
[8]	Liu L, Huang X, Xia E, et al. A cohort study comparing 4 mg and 10 mg daily doses of postoperative oestradiol therapy to prevent adhesion reformation after hysteroscopic adhesiolysis[J]. Hum Fertil(Camb), 2019, 22(3):191-197. doi: 10.1080/14647273.2018.1444798. doi: 10.1080/14647273.2018.1444798
[9]	Guo J, Li TC, Liu Y, et al. A prospective, randomized, controlled trial comparing two doses of oestrogen therapy after hysteroscopic adhesiolysis to prevent intrauterine adhesion recurrence[J]. Reprod Biomed Online, 2017, 35(5):555-561. doi: 10.1016/j.rbmo.2017.07.011. doi: 10.1016/j.rbmo.2017.07.011
[10]	Zhang Z, Li S, Deng J, et al. Aspirin inhibits endometrial fibrosis by suppressing the TGF-β1-Smad2/Smad3 pathway in intrauterine adhesions[J]. Int J Mol Med, 2020, 45(5):1351-1360. doi: 10.3892/ijmm.2020.4506. doi: 10.3892/ijmm.2020.4506
[11]	Chi Y, He P, Lei L, et al. Transdermal estrogen gel and oral aspirin combination therapy improves fertility prognosis via the promotion of endometrial receptivity in moderate to severe intrauterine adhesion[J]. Mol Med Rep, 2018, 17(5):6337-6344. doi: 10.3892/mmr.2018.8685. doi: 10.3892/mmr.2018.8685
[12]	Kunicki M, Łukaszuk K, Liss J, et al. Granulocyte colony stimulating factor treatment of resistant thin endometrium in women with frozen-thawed blastocyst transfer[J]. Syst Biol Reprod Med, 2017, 63(1):49-57. doi: 10.1080/19396368.2016.1251505. doi: 10.1080/19396368.2016.1251505 pmid: 27874292
[13]	Javaheri A, Kianfar K, Pourmasumi S, et al. Platelet-rich plasma in the management of Asherman′s syndrome: An RCT[J]. Int J Reprod Biomed, 2020, 18(2):113-120. doi: 10.18502/ijrm.v18i2.6423. doi: 10.18502/ijrm.v18i2.6423 pmid: 32259005
[14]	Kim JH, Park M, Paek JY, et al. Intrauterine Infusion of Human Platelet-Rich Plasma Improves Endometrial Regeneration and Pregnancy Outcomes in a Murine Model of Asherman′s Syndrome[J]. Front Physiol, 2020, 11:105. doi: 10.3389/fphys.2020.00105. doi: 10.3389/fphys.2020.00105
[15]	韩笑, 黄晓武. 干细胞在子宫内膜损伤后修复的研究进展[J]. 国际妇产科学杂志, 2019, 46(4):365-369. doi: 10.3969/j.issn.1674-1870.2019.04.001. doi: 10.3969/j.issn.1674-1870.2019.04.001
[16]	Cao Y, Sun H, Zhu H, et al. Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial[J]. Stem Cell Res Ther, 2018, 9(1):192. doi: 10.1186/s13287-018-0904-3. doi: 10.1186/s13287-018-0904-3
[17]	Tu CH, Yang XL, Qin XY, et al. Management of intrauterine adhesions: a novel intrauterine device[J]. Med Hypotheses, 2013, 81(3):394-396. doi: 10.1016/j.mehy.2013.05.028. doi: 10.1016/j.mehy.2013.05.028
[18]	Lin X, Wei M, Li TC, et al. A comparison of intrauterine balloon, intrauterine contraceptive device and hyaluronic acid gel in the prevention of adhesion reformation following hysteroscopic surgery for Asherman syndrome: a cohort study[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 170(2):512-516. doi: 10.1016/j.ejogrb.2013.07.018. doi: 10.1016/j.ejogrb.2013.07.018
[19]	Zhu R, Duan H, Gan L, et al. Comparison of Intrauterine Suitable Balloon and Foley Balloon in the Prevention of Adhesion after Hysteroscopic Adhesiolysis[J]. Biomed Res Int, 2018, 2018:9494101. doi: 10.1155/2018/9494101. doi: 10.1155/2018/9494101 pmid: 30533444
[20]	Yang X, Liu Y, Li TC, et al. Durations of intrauterine balloon therapy and adhesion reformation after hysteroscopic adhesiolysis: a randomized controlled trial[J]. Reprod Biomed Online, 2020, 40(4):539-546. doi: 10.1016/j.rbmo.2019.11.017. doi: S1472-6483(19)30847-8 pmid: 32199799
[21]	杨雪, 刘玉环, 夏恩兰, 等. 球囊子宫支架预防宫腔粘连术后复发的安全性分析[J]. 中国医刊, 2020, 55(5):558-560. doi: 10.3969/j.issn.1008-1070.2020.05.027. doi: 10.3969/j.issn.1008-1070.2020.05.027
[22]	Kriseman M, Schutt A, Appleton J, et al. A Novel Ultrasound-Guided Technique for Hysteroscopic Adhesiolysis in High-Risk Patients[J]. J Ultrasound Med, 2019, 38(5):1383-1387. doi: 10.1002/jum.14815. doi: 10.1002/jum.14815 pmid: 30208242
[23]	Shi X, Saravelos SH, Zhou Q, et al. Prevention of postoperative adhesion reformation by intermittent intrauterine balloon therapy: a randomised controlled trial[J]. BJOG, 2019, 126(10):1259-1266. doi: 10.1111/1471-0528.15843. doi: 10.1111/1471-0528.15843
[24]	Azumaguchi A, Henmi H, Saito T. Efficacy of silicone sheet as a personalized barrier for preventing adhesion reformation after hysteroscopic adhesiolysis of intrauterine adhesions[J]. Reprod Med Biol, 2019, 18(4):378-383. doi: 10.1002/rmb2.12294. doi: 10.1002/rmb2.12294 pmid: 31607798
[25]	Chiu CS, Hwu YM, Lee RK, et al. Intrauterine adhesion prevention with Malecot catheter after hysteroscopic myomectomy: A novel approach[J]. Taiwan J Obstet Gynecol, 2020, 59(1):56-60. doi: 10.1016/j.tjog.2019.11.008. doi: 10.1016/j.tjog.2019.11.008
[26]	Huang H, Xu B, Cheng C, et al. A novel intrauterine stent for prevention of intrauterine adhesions[J]. Ann Transl Med, 2020, 8(4):61. doi: 10.21037/atm.2019.12.82. doi: 10.21037/atm.2019.12.82 pmid: 32175355
[27]	Cai Y, Wu F, Yu Y, et al. Porous scaffolds from droplet microfluidics for prevention of intrauterine adhesion[J]. Acta Biomater, 2019, 84:222-230. doi: 10.1016/j.actbio.2018.11.016. doi: 10.1016/j.actbio.2018.11.016
[28]	Vasvani S, Kulkarni P, Rawtani D. Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies[J]. Int J Biol Macromol, 2020, 151:1012-1029. doi: 10.1016/j.ijbiomac.2019.11.066. doi: S0141-8130(19)36547-X pmid: 31715233
[29]	Liu H, Xu Y, Yi N, et al. Efficacy and Safety of Hyaluronic Acid Gel for the Prevention of Intrauterine Adhesion: A Meta-Analysis of Randomized Clinical Trials[J]. Gynecol Obstet Invest, 2018, 83(3):227-233. doi: 10.1159/000486674. doi: 10.1159/000486674
[30]	Hooker AB, de Leeuw R, van de Ven PM, et al. Prevalence of intrauterine adhesions after the application of hyaluronic acid gel after dilatation and curettage in women with at least one previous curettage: short-term outcomes of a multicenter, prospective randomized controlled trial[J]. Fertil Steril, 2017, 107(5):1223-1231.e3. doi: 10.1016/j.fertnstert.2017.02.113. doi: 10.1016/j.fertnstert.2017.02.113
[31]	Fei Z, Bin Z, Xin X, et al. Meta-analysis on the use of hyaluronic acid gel to prevent recurrence of intrauterine adhesion after hysteroscopic adhesiolysis[J]. Taiwan J Obstet Gynecol, 2019, 58(6):731-736. doi: 10.1016/j.tjog.2019.09.002. doi: 10.1016/j.tjog.2019.09.002
[32]	Amer MI, Abd-El-Maeboud K, Alloub A, Amnion graft as a possible source of stem cells for endometrial regeneration after lysis of severe intrauterine adhesions[J]. Middle East Fertil Soc J, 2012, 17(1):54-56. doi: 10.1016/j.mefs.2011.12.001. doi: 10.1016/j.mefs.2011.12.001
[33]	Farhadihosseinabadi B, Farahani M, Tayebi T, et al. Amniotic membrane and its epithelial and mesenchymal stem cells as an appropriate source for skin tissue engineering and regenerative medicine[J]. Artif Cells Nanomed Biotechnol, 2018, 46(sup2):431-440. doi: 10.1080/21691401.2018.1458730. doi: 10.1080/21691401.2018.1458730 pmid: 29687742
[34]	祝鑫瑜, 段华, 王欣, 等. 羊膜制品对宫腔粘连分离术后宫腔渗出液中细胞因子的影响及意义[J]. 中国微创外科杂志, 2016, 16(10):922-926,935. doi: 10.3969/j.issn.1009-6604.2016.10.015. doi: 10.3969/j.issn.1009-6604.2016.10.015
[35]	Peng X, Li T, Zhao Y, et al. Safety and Efficacy of Amnion Graft in Preventing Reformation of Intrauterine Adhesions[J]. J Minim Invasive Gynecol, 2017, 24(7):1204-1210. doi: 10.1016/j.jmig.2017.08.005. doi: 10.1016/j.jmig.2017.08.005
[36]	Li C, Cai A, Sun C, et al. The study on the safety and efficacy of amnion graft for preventing the recurrence of moderate to severe intrauterine adhesions[J]. Genes Dis, 2020, 7(2):266-271. doi: 10.1016/j.gendis.2019.03.003. doi: 10.1016/j.gendis.2019.03.003
[37]	Gan L, Duan H, Sun FQ, et al. Efficacy of freeze-dried amnion graft following hysteroscopic adhesiolysis of severe intrauterine adhesions[J]. Int J Gynaecol Obstet, 2017, 137(2):116-122. doi: 10.1002/ijgo.12112. doi: 10.1002/ijgo.12112 pmid: 28170094
[38]	Zheng F, Zhu B, Liu Y, et al. Meta-analysis of the use of amniotic membrane to prevent recurrence of intrauterine adhesion after hysteroscopic adhesiolysis[J]. Int J Gynaecol Obstet, 2018, 143(2):145-149. doi: 10.1002/ijgo.12635. doi: 10.1002/ijgo.12635 pmid: 30073656
[39]	Xu W, Zhang Y, Yang Y, et al. Effect of early second-look hysteroscopy on reproductive outcomes after hysteroscopic adhesiolysis in patients with intrauterine adhesion, a retrospective study in China[J]. Int J Surg, 2018, 50:49-54. doi: 10.1016/j.ijsu.2017.11.040. doi: 10.1016/j.ijsu.2017.11.040
[40]	Liu L, Yang H, Guo Y, et al. The impact of chronic endometritis on endometrial fibrosis and reproductive prognosis in patients with moderate and severe intrauterine adhesions: a prospective cohort study[J]. Fertil Steril, 2019, 111（5）:1002-1010.e2. doi: 10.1016/j.fertnstert.2019.01.006. doi: 10.1016/j.fertnstert.2019.01.006